FTC Castigates FDA For Lax Oversight Of Homeopathic Products

The Federal Trade Commission criticized FDA's regulatory oversight of homeopathic products as lax, arguing FDA’s policies are at odds with FTC’s more robust requirements for advertising claims on labels and could be a detriment to consumers. The FTC called for a more stringent FDA oversight framework that includes proof of efficacy for homeopathic products, a shift in policy that could have a drastic impact on the multibillion industry. In public comments sent to FDA Friday (Aug. 21), which were approved...